SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets closed

Sanofi (SNY)


NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
46.39+0.49 (+1.07%)
At close: 4:00PM EDT
People also watch
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close45.90
Open46.43
Bid0.00 x
Ask0.00 x
Day's Range46.19 - 46.49
52 Week Range36.81 - 46.49
Volume1,556,953
Avg. Volume1,522,990
Market Cap115.85B
Beta0.75
PE Ratio (TTM)24.00
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.46%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com5 hours ago

    K-Mart to Sell Cheaper EpiPen Alternative

    K-Mart will charge cash paying customers $199 for a two-pack vs. Mylan's $643.

  • Business Wire8 hours ago

    New Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy

    Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio® on cortical gray matter atrophy in patients with a first clinical episode suggestive of MS will be presented at the 69th American Academy of Neurology Annual Meeting.

  • PR Newswire8 hours ago

    Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

    BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 25, 2017 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new supplemental Biologics License Application (sBLA) for a once-monthly (every four weeks), 300 mg dose of Praluent® (alirocumab) Injection for the treatment of adults with high low-density lipoprotein (LDL) cholesterol. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL cholesterol. The effect of Praluent on cardiovascular (CV) morbidity and mortality has not been determined.